Previous close | 28.71 |
Open | 29.85 |
Bid | 29.85 x 100 |
Ask | 30.01 x 100 |
Day's range | 29.17 - 30.26 |
52-week range | 19.34 - 63.08 |
Volume | |
Avg. volume | 453,914 |
Market cap | 1.498B |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.60 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 56.00 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Insights into Financial Performance and Strategic Developments
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasda